A major international collaboration led by Melbourne researchers has discovered that the world’s most widespread malaria parasite infects humans by hijacking a protein the body cannot live without.
The researchers were then able to successfully develop antibodies that disabled the parasite from carrying out this activity.
The study, led by the Walter and Eliza Hall Institute’s Associate Professor Wai-Hong Tham and Dr Jakub Gruszczyk, found that the deadly malaria parasite Plasmodium vivax (P. vivax) causes infection through latching onto the human transferrin receptor protein, which is crucial for iron delivery into the body’s young red blood cells.
Published today in Science, the discovery has solved a mystery that researchers have been grappling with for decades.
Associate Professor Tham, who is also a HHMI-Wellcome International Research Scholar, said the collective efforts of teams from Australia, New Zealand, Singapore, Thailand, United Kingdom, United States, Brazil and Germany had brought the world closer to a potential effective vaccine against P.vivax malaria.
“P. vivax currently inflicts a huge burden on global health. It is the most common malaria parasite in countries outside of Africa, with more than 16 million clinical cases recorded each year.
“The parasite can lie dormant in the liver for months on end without causing any symptoms, which makes it very sneaky and difficult to treat,” Associate Professor Tham said.
“We now know that P. vivax is hijacking the human transferrin receptor which is essential for transporting iron into the body’s young red blood cells.
“Being able to stop P. vivax from latching onto this receptor and infliltrating the blood is a major breakthrough and important step towards malaria elimination,” she said.
Dr Gruszczyk said once the teams understood how the parasite was gaining entry into the cells, they were able to design antibodies to block the mode of access.
“Using the Australian Synchrotron in Melbourne, we generated a 3D map of the parasite protein which is the mechanism P. vivax uses to latch onto the human transferrin receptor and enter the young red blood cells.
“This map provided an unprecedented view of the parasite protein’s shape, which guided the design of antibodies to block P. vivax from gaining entry into the human cells,” Dr Gruszczyk said.
Associate Professor Tham said they were thrilled to see the antibodies successfully block P. vivax invasion using parasites from both Thailand and Brazil. “We are now looking to include collaborative partners in the Pacific, so we can further test the effectiveness of our antibodies,” she said.
Study collaborator Dr Jonathan Abraham from Harvard University said the results of the new study aligned with a growing body of evidence that could be used to target multiple infectious diseases.
“Transferrin receptor is also co-opted by five viruses that cause Ebola-like diseases in South America. These diseases are known as New World haemorrhagic fevers.
“Our increasing understanding of how several pathogens are taking advantage of transferrin receptor, means we are getting closer to disrupting infection for a number of deadly diseases,” Dr Abraham said.
The Latest on: Malaria parasite
- How Genetically Edited Doublesex Mosquitoes Could Save Millions Of Lives on April 17, 2019 at 12:01 pm
You can read below about how gene editing could play a key role in eradicating malaria. I’ve also written about amazing advances in tracking the disease and how the parasite is a deadly shapeshifter. ... […]
- Malaria Treatment Market: High Prevalence and Disease Burden of Malaria Is Expected to Drive the Market on April 16, 2019 at 11:06 pm
Malaria is typically prevalent in hot climate. Anopheles mosquito, that transfers malaria parasite from one person to another, thrives in warm, moist climate where ponds of water offer it the perfect ... […]
- Promising malaria vaccine to be tested in first large field trial on April 16, 2019 at 12:58 pm
PfSPZ works by eliciting an immune response against the malaria parasite Plasmodium falciparum. It is made of sporozoites (SPZ), the stage in the malaria parasite’s life cycle that infected mosquitoes ... […]
- After 30 years, Glaxo shows the right ‘PATH’ to eradicate malaria on April 16, 2019 at 9:21 am
The vaccine, developed with the non-profit organisation PATH, comes at a critical time and marks a milestone in the battle against the parasite that causes malaria. But the injection is a pioneer, not ... […]
- Malaria vaccination set to begin in Africa this month on April 16, 2019 at 7:21 am
The malaria parasite's uncanny ability to resist drugs and insecticides due to its complicated genes is making efforts to eliminate the disease more difficult. GlaxoSmithKline Plc invested $1 billion ... […]
- Malaria vaccine pilot programme to start in Africa this month on April 16, 2019 at 12:23 am
The technology is already being used to breed mosquitoes that spread sterility to deplete their numbers. The malaria parasite turns out to have greater genetic diversity than previously believed, ... […]
- Malaria Vaccine Took 30 Years. It's Still a Work in Progress on April 15, 2019 at 9:00 pm
The vaccine, developed with the non-profit organization PATH, comes at a critical time and marks a milestone in the battle against the parasite that causes malaria. But the injection is more pioneer ... […]
- Under the microscope: Ayush ministry’s dubious claims about Ayurvedic drugs for diabetes, malaria on April 14, 2019 at 8:07 pm
A Facebook post of Ministry of AYUSH claimed  that CCRAS has developed a drug called AYUSH-64 to counter the developing drug resistance to malaria parasite and the widespread nature of the ... […]
- Ghana gets 400,000 doses of new malaria vaccine for pilot on April 12, 2019 at 11:49 pm
The plasmodium falciparum, is the predominant malaria parasite which causes 80 to 90 percent of severe morbidity and mortality mostly in children under 5 and pregnant women. The vaccine stimulates the ... […]
- First anti-malaria vaccines ready for pilot in Ghana on April 12, 2019 at 4:47 am
The vaccine acts against Plasmodium falciparum, the most deadly malaria parasite in the world and the most prevalent in Africa. They will be administered through the routine national immunisation ... […]
via Google News and Bing News